Human adipose-tissue derived mesenchymal stem cells induce functional de-novo regulatory T cells with methylated FOXP3 gene DNA

Clinical and Experimental Immunology

Volumn 173, Issue 2, 2013, Pages 343-354

  Engela, A U ^a   Hoogduijn, M J ^a   Boer, K ^a   Litjens, N H R ^a   Betjes, M G H ^a   Weimar, W ^a   Baan, C C ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Immunosuppression; Induction; Interleukin 2 receptor signalling; Mesenchymal stem cells; Regulatory T cells

Indexed keywords

INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 7 RECEPTOR; TRANSCRIPTION FACTOR FOXP3;

ADIPOSE TISSUE DERIVED MESENCHYMAL STEM CELL; ARTICLE; CD4+ T LYMPHOCYTE; CELL FRACTIONATION; CELL FUNCTION; CELL PROLIFERATION; CELL STIMULATION; CONTROLLED STUDY; DNA METHYLATION; EFFECTOR CELL; GENE; HUMAN; HUMAN CELL; HUMAN TISSUE; KIDNEY DONOR; MESENCHYMAL STEM CELL; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION;

IMMUNOSUPPRESSION; INDUCTION; INTERLEUKIN-2 RECEPTOR SIGNALLING; MESENCHYMAL STEM CELLS; REGULATORY T CELLS;

ADIPOSE TISSUE; ANTIBODIES, MONOCLONAL; ANTIGENS, CD4; CELL SEPARATION; CELL- AND TISSUE-BASED THERAPY; CELLS, CULTURED; DNA METHYLATION; FLOW CYTOMETRY; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; IMMUNE TOLERANCE; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; INTERLEUKIN-7 RECEPTOR ALPHA SUBUNIT; LYMPHOCYTE ACTIVATION; MESENCHYMAL STROMAL CELLS; RECEPTORS, INTERLEUKIN-2; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES, HELPER-INDUCER; T-LYMPHOCYTES, REGULATORY;

EID: 84879997952     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12120     Document Type: Article

References (76)

1. Hoogduijn MJ, Crop MJ, Peeters AM etal. Human heart, spleen, and perirenal fat-derived mesenchymal stem cells have immunomodulatory capacities. Stem Cells Dev 2007; 16:597-604.
2. Pittenger MF, Mackay AM, Beck SC etal. Multilineage potential of adult human mesenchymal stem cells. Science 1999; 284:143-147.
3. Zuk PA, Zhu M, Ashjian P etal. Human adipose tissue is a source of multipotent stem cells. Mol Biol Cell 2002; 13:4279-4295.
4. Antonucci I, Stuppia L, Kaneko Y etal. Amniotic fluid as a rich source of mesenchymal stromal cells for transplantation therapy. Cell Transplant 2011; 20:789-795.
5. Figueroa FE, Carrion F, Villanueva S, Khoury M. Mesenchymal stem cell treatment for autoimmune diseases: a critical review. Biol Res 2012; 45:269-277.
6. Dominguez-Bendala J, Lanzoni G, Inverardi L, Ricordi C. Concise review: mesenchymal stem cells for diabetes. Stem Cells Transl Med 2012; 1:59-63.
7. Bernardo ME, Fibbe WE. Safety and efficacy of mesenchymal stromal cell therapy in autoimmune disorders. Ann NY Acad Sci 2012; 1266:107-117.
8. Le Blanc K, Frassoni F, Ball L etal. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 2008; 371:1579-1586.
9. Casiraghi F, Azzollini N, Cassis P etal. Pretransplant infusion of mesenchymal stem cells prolongs the survival of a semiallogeneic heart transplant through the generation of regulatory T cells. J Immunol 2008; 181:3933-3946.
10. Popp FC, Eggenhofer E, Renner P etal. Mesenchymal stem cells can induce long-term acceptance of solid organ allografts in synergy with low-dose mycophenolate. Transpl Immunol 2008; 20:55-60.
11. Zografou A, Tsigris C, Papadopoulos O etal. Improvement of skin-graft survival after autologous transplantation of adipose-derived stem cells in rats. J Plast Reconstr Aesthet Surg 2011; 64:1647-1656.
12. Roemeling-van Rhijn M, Weimar W, Hoogduijn MJ. Mesenchymal stem cells: application for solid-organ transplantation. Curr Opin Organ Transplant 2012; 17:55-62.
13. Krampera M, Cosmi L, Angeli R etal. Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells 2006; 24:386-398.
14. Crop MJ, Baan CC, Korevaar SS etal. Inflammatory conditions affect gene expression and function of human adipose tissue-derived mesenchymal stem cells. Clin Exp Immunol 2010; 162:474-486.
15. Bartholomew A, Sturgeon C, Siatskas M etal. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol 2002; 30:42-48.
16. Corcione A, Benvenuto F, Ferretti E etal. Human mesenchymal stem cells modulate B-cell functions. Blood 2006; 107:367-372.
17. Sotiropoulou PA, Perez SA, Gritzapis AD, Baxevanis CN, Papamichail M. Interactions between human mesenchymal stem cells and natural killer cells. Stem Cells 2006; 24:74-85.
18. Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005; 105:1815-1822.
19. Jiang XX, Zhang Y, Liu B etal. Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. Blood 2005; 105:4120-4126.
20. Di Nicola M, Carlo-Stella C, Magni M etal. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 2002; 99:3838-3843.
21. Crop MJ, Baan CC, Korevaar SS etal. Donor-derived mesenchymal stem cells suppress alloreactivity of kidney transplant patients. Transplantation 2009; 87:896-906.
22. Augello A, Tasso R, Negrini SM etal. Bone marrow mesenchymal progenitor cells inhibit lymphocyte proliferation by activation of the programmed death 1 pathway. Eur J Immunol 2005; 35:1482-1490.
23. Groh ME, Maitra B, Szekely E, Koc ON. Human mesenchymal stem cells require monocyte-mediated activation to suppress alloreactive T cells. Exp Hematol 2005; 33:928-934.
24. Deuse T, Stubbendorff M, Tang-Quan K etal. Immunogenicity and immunomodulatory properties of umbilical cord lining mesenchymal stem cells. Cell Transplant 2011; 20:655-667.
25. Sato K, Ozaki K, Oh I etal. Nitric oxide plays a critical role in suppression of T-cell proliferation by mesenchymal stem cells. Blood 2007; 109:228-234.
26. Nasef A, Mathieu N, Chapel A etal. Immunosuppressive effects of mesenchymal stem cells: involvement of HLA-G. Transplantation 2007; 84:231-237.
27. Meisel R, Zibert A, Laryea M, Gobel U, Daubener W, Dilloo D. Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2, 3-dioxygenase-mediated tryptophan degradation. Blood 2004; 103:4619-4621.
28. Hoogduijn MJ, Popp F, Verbeek R etal. The immunomodulatory properties of mesenchymal stem cells and their use for immunotherapy. Int Immunopharmacol 2010; 10:1496-1500.
29. Engela AU, Baan CC, Peeters AM, Weimar W, Hoogduijn MJ. Interaction between adipose-tissue derived mesenchymal stem cells and regulatory T cells. Cell Transplant 2012; 22:41-54.
30. + regulatory T cells. Clin Exp Immunol 2009; 156:149-160.
31. Di Ianni M, Del Papa B, De Ioanni M etal. Mesenchymal cells recruit and regulate T regulatory cells. Exp Hematol 2008; 36:309-318.
32. Gonzalez MA, Gonzalez-Rey E, Rico L, Buscher D, Delgado M. Adipose-derived mesenchymal stem cells alleviate experimental colitis by inhibiting inflammatory and autoimmune responses. Gastroenterology 2009; 136:978-989.
33. Ge W, Jiang J, Baroja ML etal. Infusion of mesenchymal stem cells and rapamycin synergize to attenuate alloimmune responses and promote cardiac allograft tolerance. Am J Transplant 2009; 9:1760-1772.
34. Kavanagh H, Mahon BP. Allogeneic mesenchymal stem cells prevent allergic airway inflammation by inducing murine regulatory T cells. Allergy 2011; 66:523-531.
35. Perico N, Casiraghi F, Introna M etal. Autologous mesenchymal stromal cells and kidney transplantation: a pilot study of safety and clinical feasibility. Clin J Am Soc Nephrol 2011; 6:412-422.
36. Bilate AM, Lafaille JJ. Induced CD4+Foxp3+ regulatory T cells in immune tolerance. Annu Rev Immunol 2012; 30:733-758.
37. Baron U, Floess S, Wieczorek G etal. DNA demethylation in the human FOXP3 locus discriminates regulatory T cells from activated FOXP3(+) conventional T cells. Eur J Immunol 2007; 37:2378-2389.
38. Eggenhofer E, Benseler V, Kroemer A etal. Mesenchymal stem cells are short-lived and do not migrate beyond the lungs after intravenous infusion. Front Immunol 2012; 3:297.
39. Wieczorek G, Asemissen A, Model F etal. Quantitative DNA methylation analysis of FOXP3 as a new method for counting regulatory T cells in peripheral blood and solid tissue. Cancer Res 2009; 69:599-608.
40. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001; 25:402-408.
41. Ge W, Jiang J, Arp J, Liu W, Garcia B, Wang H. Regulatory T-cell generation and kidney allograft tolerance induced by mesenchymal stem cells associated with indoleamine 2, 3-dioxygenase expression. Transplantation 2010; 90:1312-1320.
42. Casiraghi F, Azzollini N, Todeschini M etal. Localization of mesenchymal stromal cells dictates their immune or proinflammatory effects in kidney transplantation. Am J Transplant 2012; 12:2373-2383.
43. Furtado GC, Curotto de Lafaille MA, Kutchukhidze N, Lafaille JJ. Interleukin 2 signaling is required for CD4(+) regulatory T cell function. J Exp Med 2002; 196:851-857.
44. Curotto de Lafaille MA, Lino AC, Kutchukhidze N, Lafaille JJ. CD25- T cells generate CD25+Foxp3+ regulatory T cells by peripheral expansion. J Immunol 2004; 173:7259-7268.
45. Curotto de Lafaille MA, Lafaille JJ. Natural and adaptive foxp3+ regulatory T cells: more of the same or a division of labor? Immunity 2009; 30:626-635.
46. Wu Y, Borde M, Heissmeyer V etal. FOXP3 controls regulatory T cell function through cooperation with NFAT. Cell 2006; 126:375-387.
47. Marson A, Kretschmer K, Frampton GM etal. Foxp3 occupancy and regulation of key target genes during T-cell stimulation. Nature 2007; 445:931-935.
48. Zheng Y, Josefowicz SZ, Kas A, Chu TT, Gavin MA, Rudensky AY. Genome-wide analysis of Foxp3 target genes in developing and mature regulatory T cells. Nature 2007; 445:936-940.
49. Ono M, Yaguchi H, Ohkura N etal. Foxp3 controls regulatory T-cell function by interacting with AML1/Runx1. Nature 2007; 446:685-689.
50. Wing K, Onishi Y, Prieto-Martin P etal. CTLA-4 control over Foxp3+ regulatory T cell function. Science 2008; 322:271-275.
51. Thornton AM, Korty PE, Tran DQ etal. Expression of Helios, an Ikaros transcription factor family member, differentiates thymic-derived from peripherally induced Foxp3+ T regulatory cells. J Immunol 2010; 184:3433-3441.
52. Akimova T, Beier UH, Wang L, Levine MH, Hancock WW. Helios expression is a marker of T cell activation and proliferation. PLoS ONE 2011; 6:e24226.
53. Gottschalk RA, Corse E, Allison JP. Expression of Helios in peripherally induced Foxp3+ regulatory T cells. J Immunol 2012; 188:976-980.
54. Amarnath S, Mangus CW, Wang JC etal. The PDL1-PD1 axis converts human TH1 cells into regulatory T cells. Sci Transl Med 2011; 3:111ra20.
55. Tatara R, Ozaki K, Kikuchi Y etal. Mesenchymal stromal cells inhibit Th17 but not regulatory T-cell differentiation. Cytotherapy 2011; 13:686-694.
56. Ghannam S, Pene J, Torcy-Moquet G, Jorgensen C, Yssel H. Mesenchymal stem cells inhibit human Th17 cell differentiation and function and induce a T regulatory cell phenotype. J Immunol 2010; 185:302-312.
57. Tasso R, Ilengo C, Quarto R, Cancedda R, Caspi RR, Pennesi G. Mesenchymal stem cells induce functionally active T-regulatory lymphocytes in a paracrine fashion and ameliorate experimental autoimmune uveitis. Invest Ophthalmol Vis Sci 2012; 53:786-793.
58. Mougiakakos D, Jitschin R, Johansson CC, Okita R, Kiessling R, Le Blanc K. The impact of inflammatory licensing on heme oxygenase-1-mediated induction of regulatory T cells by human mesenchymal stem cells. Blood 2011; 117:4826-4835.
59. Cheng G, Yu A, Malek TR. T-cell tolerance and the multi-functional role of IL-2R signaling in T-regulatory cells. Immunol Rev 2011; 241:63-76.
60. Koch MA, Tucker-Heard G, Perdue NR, Killebrew JR, Urdahl KB, Campbell DJ. The transcription factor T-bet controls regulatory T cell homeostasis and function during type 1 inflammation. Nat Immunol 2009; 10:595-602.
61. Haniffa MA, Wang XN, Holtick U etal. Adult human fibroblasts are potent immunoregulatory cells and functionally equivalent to mesenchymal stem cells. J Immunol 2007; 179:1595-1604.
62. Jones S, Horwood N, Cope A, Dazzi F. The antiproliferative effect of mesenchymal stem cells is a fundamental property shared by all stromal cells. J Immunol 2007; 179:2824-2831.
63. Le Blanc K, Rasmusson I, Sundberg B etal. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 2004; 363:1439-1441.
64. Daniel C, Weigmann B, Bronson R, von Boehmer H. Prevention of type 1 diabetes in mice by tolerogenic vaccination with a strong agonist insulin mimetope. J Exp Med 2011; 208:1501-1510.
65. Kohm AP, Carpentier PA, Anger HA, Miller SD. Cutting edge: CD4+CD25+ regulatory T cells suppress antigen-specific autoreactive immune responses and central nervous system inflammation during active experimental autoimmune encephalomyelitis. J Immunol 2002; 169:4712-4716.
66. Bushell A, Wood K. GITR ligation blocks allograft protection by induced CD25+CD4+ regulatory T cells without enhancing effector T-cell function. Am J Transplant 2007; 7:759-768.
67. Nadig SN, Wieckiewicz J, Wu DC etal. In vivo prevention of transplant arteriosclerosis by ex vivo-expanded human regulatory T cells. Nat Med 2010; 16:809-813.
68. Issa F, Hester J, Goto R, Nadig SN, Goodacre TE, Wood K. Ex vivo-expanded human regulatory T cells prevent the rejection of skin allografts in a humanized mouse model. Transplantation 2010; 90:1321-1327.
69. Ermann J, Hoffmann P, Edinger M etal. Only the CD62L+ subpopulation of CD4+CD25+ regulatory T cells protects from lethal acute GVHD. Blood 2005; 105:2220-2226.
70. Shin HJ, Baker J, Leveson-Gower DB, Smith AT, Sega EI, Negrin RS. Rapamycin and IL-2 reduce lethal acute graft-versus-host disease associated with increased expansion of donor type CD4+CD25+Foxp3+ regulatory T cells. Blood 2011; 118:2342-2350.
71. Trzonkowski P, Bieniaszewska M, Juscinska J etal. First-in-man clinical results of the treatment of patients with graft versus host disease with human ex vivo expanded CD4+CD25+CD127- T regulatory cells. Clin Immunol 2009; 133:22-26.
72. Brunstein CG, Miller JS, Cao Q etal. Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. Blood 2011; 117:1061-1070.
73. Di Ianni M, Falzetti F, Carotti A etal. Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. Blood 2011; 117:3921-3928.
74. Koreth J, Matsuoka K, Kim HT etal. Interleukin-2 and regulatory T cells in graft-versus-host disease. N Engl J Med 2011; 365:2055-2066.
75. Battaglia M, Stabilini A, Roncarolo MG. Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells. Blood 2005; 105:4743-4748.
76. Sewgobind VD, van der Laan LJ, Kho MM etal. Characterization of rabbit antithymocyte globulins-induced CD25+ regulatory T cells from cells of patients with end-stage renal disease. Transplantation 2010; 89:655-666.